Lento Bio Raises $680,000 in Oversubscribed Seed Round
Lento Bio, a preclinical pharmaceutical company developing small-molecule therapeutics to restore ocular lens flexibility and near vision in presbyopia patients, has announced in a press release they have raised $680,000 in funding during their recent oversubscribed seed round. The lead investor for the round is Ichor Life Sciences, which provided $400,000 in funding. The seed round will be used to conduct research and testing that will establish proof of concept for Lento Bio's therapeutics and help optimize lead compounds in early-stage pre-clinical studies. More information can be found athttps://www.accesswire.com/714772/Lento-Bio-Raises-680000-in-Oversubscribed-Seed-Round-Led-by-Ichor-Life-Sciences.